StockData

Aytu BioPharma vs Tonix Pharmaceuticals

AYTU and TNXP side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How AYTU and TNXP compare

Tonix Pharmaceuticals is the larger company, worth 1.7 times as much as Aytu BioPharma ($50.4M against $28.9M).

Tonix Pharmaceuticals grew revenue faster over the last twelve months (196% versus −13.3% for Aytu BioPharma).

Aytu BioPharma keeps more of each dollar of sales as profit, with a net margin of −24.8% compared with −549% at Tonix Pharmaceuticals.

Tonix Pharmaceuticals scores higher on the StockData Score (10 against 9 for Aytu BioPharma), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricAYTUTNXP
Size and price
Market cap$28.9M$50.4M
Share price$2.66$2.94
Change, 1 year27.3%−81.5%
Change, 5 years−93.2%−100.0%
Beta (5Y)−0.050.75
Employees76142
StockData Score
Total score910 (better)
Valuation score33
Growth score02 (better)
Performance score3 (better)0
Health score35 (better)
Dividend score00
Valuation
P/S0.5× (better)1.7×
P/B0.8×0.2× (better)
P/FCF8.9×–
FCF yield11.3% (better)−314%
Fair value$8.97$16.91
Margin of safety70.4%82.6% (better)
Growth
Revenue growth (TTM)−13.3%196% (better)
Revenue growth, 5Y average−2.6%–
Profitability
Gross margin64.0%83.8% (better)
Operating margin−14.4% (better)−568%
Net margin−24.8% (better)−549%
FCF margin5.6% (better)−543%
Return on equity−52.6% (better)−81.8%
Return on invested capital−63.5% (better)−298%
Financial health
Debt / equity0.31 (better)0.00
Interest coverage−4.4×–
Current ratio1.136.61 (better)
Altman Z-score−4.02 (better)−5.42
Piotroski F-score36 (better)
Dividends and buybacks
Buyback yield–−427%
Shareholder yield0.00% (better)−427%
Ownership
Held by institutions45.3%54.6%
Held by insiders15.1%0.27%
Insider net buying, 12 months–$479K
Short interest, % of float3.3%19.4%

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.